Cancer Family
Skin Neoplasm
CI-CAN-00000051Explore in graph →
Non-malignant346 active trials14 approved drugs74 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000051Explore in graph →
Clinical trials
1,424 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02900248 | CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice(N1) | terminated | — | 23 | CureOneOTHER | 1 | Apr 2, 2019 | clinicaltrials |
| NCT02303041 | Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma | terminated | Phase 2 | 10 | Anne ChangOTHER | 1 | Jan 29, 2019 | clinicaltrials |
| NCT02061449 | Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma | terminated | Phase 1 | 3 | NYU Langone HealthOTHER | 1 | Dec 24, 2018 | clinicaltrials |
| NCT02556463 | A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors | terminated | Phase 1 | 53 | MedImmune LLCINDUSTRY | 3 | Dec 19, 2018 | clinicaltrials |
| NCT02327390 | Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma | terminated | Phase 1 | 3 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 6, 2018 | clinicaltrials |
| NCT01764607 | Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma | terminated | Phase 2 | 1 | University of FloridaOTHER | 1 | Nov 14, 2018 | clinicaltrials |
| NCT00958074 | Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma | terminated | Phase 2 | 11 | University of WashingtonOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT02602067 | 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients(Tenatumomab) | terminated | Phase 1 | 2 | sigma-tau i.f.r. S.p.A.INDUSTRY | 2 | Sep 18, 2018 | clinicaltrials |
| NCT01663571 | STAT3 in T Cells: At The Crossroads of Inflammation and Cancer | terminated | — | 35 | NYU Langone HealthOTHER | 1 | Sep 17, 2018 | clinicaltrials |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | terminated | Phase 1 | 4 | Mayo ClinicOTHER | 1 | Sep 5, 2018 | clinicaltrials |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 1 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01823679 | Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin | terminated | Phase 2 | 2 | Stanford UniversityOTHER | 1 | Apr 12, 2018 | clinicaltrials |
| NCT01609530 | Pulsed 1064nm Nd:YAG in the Treatment of Verruca Vulgaris Versus Conventional Therapy With Liquid Nitrogen Cryotherapy | terminated | N/A | 31 | Trinity Health MichiganOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT01984892 | Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)(Hiltonol) | terminated | Phase 2 | 8 | Nina BhardwajOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT01187446 | Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides | terminated | Phase 1 / Phase 2 | 28 | Stanford UniversityOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT02076243 | Treatment With Nab-paclitaxel in Cutaneous SCC | terminated | Phase 2 | 2 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Oct 25, 2017 | clinicaltrials |
| NCT02111863 | Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Sep 19, 2017 | clinicaltrials |
| NCT01271907 | Drosophila-generated CTL | terminated | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2017 | clinicaltrials |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | terminated | N/A | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 28, 2017 | clinicaltrials |
| NCT00985140 | Phase 2 Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides | terminated | — | 13 | Stanford UniversityOTHER | 1 | Jun 2, 2017 | clinicaltrials |
| NCT01059305 | Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin | terminated | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT01637090 | Everolimus in Treating Cutaneous T-cell Lymphoma(CTCL) | terminated | Phase 2 | 3 | Adam LernerOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT01307618 | Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Oct 24, 2016 | clinicaltrials |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2016 | clinicaltrials |
| NCT02221843 | Sunbit UV Measuring Device to Track Sun Behavior | terminated | — | 10 | University of ZurichOTHER | 1 | Jul 13, 2016 | clinicaltrials |
| NCT01059656 | Phase II Pazopanib Study in Advanced Dermatofibrosarcomas(DFSP-PAZO) | terminated | Phase 2 | 23 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 1, 2016 | clinicaltrials |
| NCT01468818 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | terminated | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Jun 27, 2016 | clinicaltrials |
| NCT01556828 | Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing | terminated | — | 70 | Stanford UniversityOTHER | 1 | Jun 24, 2016 | clinicaltrials |
| NCT01808950 | Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 4 | Spirig Pharma Ltd.INDUSTRY | 2 | Jun 22, 2016 | clinicaltrials |
| NCT01120275 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma | terminated | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Jun 14, 2016 | clinicaltrials |
| NCT01045928 | Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 5 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 26, 2015 | clinicaltrials |
| NCT01236573 | Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes | terminated | Phase 1 / Phase 2 | 34 | National Institutes of Health Clinical Center (CC)NIH | 1 | Nov 26, 2015 | clinicaltrials |
| NCT00610311 | Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma | terminated | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00612222 | Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01495572 | Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Oct 15, 2015 | clinicaltrials |
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection | terminated | Phase 1 | 72 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2015 | clinicaltrials |
| NCT00274651 | A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas(PXD101-CLN-6) | terminated | Phase 2 | 53 | Valerio TherapeuticsINDUSTRY | 5 | Jul 28, 2015 | clinicaltrials |
| NCT00129415 | Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions | terminated | Phase 1 / Phase 2 | 28 | University of MichiganOTHER | 1 | May 22, 2015 | clinicaltrials |
| NCT00278018 | Peritumoral Injection of Immature Dendritic Cells to Irradiated Skin Metastases of Solid Tumors | terminated | Phase 1 / Phase 2 | 20 | Hadassah Medical OrganizationOTHER | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00994240 | Cure Rates of Superficial Basal Cell Carcinoma (BCC) EDC | terminated | N/A | 85 | University of Wisconsin, MadisonOTHER | 1 | Feb 27, 2015 | clinicaltrials |
| NCT01369888 | Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jan 27, 2015 | clinicaltrials |
| NCT01193036 | Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems | terminated | — | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 8, 2015 | clinicaltrials |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | terminated | Phase 1 | 35 | Yale UniversityOTHER | 1 | Jul 2, 2014 | clinicaltrials |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | terminated | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 2 | May 1, 2014 | clinicaltrials |
| NCT00863395 | Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma(CTCL) | terminated | Phase 1 / Phase 2 | 6 | University of MinnesotaOTHER | 1 | Mar 31, 2014 | clinicaltrials |
| NCT02080962 | Hypofractionated Radiotherapy for Nonmelanoma Skin Cancer | terminated | Phase 2 | 10 | Barretos Cancer HospitalOTHER | 1 | Mar 7, 2014 | clinicaltrials |
| NCT00096005 | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00101205 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | terminated | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Apr 2, 2019source: clinicaltrials